Vaccinex, Inc. · OTC:VCNX
Vaccinex — Investor Presentation (September 2018)
30 slides from Vaccinex's investor presentation, Sep 26, 2018
Slide 1: VX15 (pepinemab) Antibody Treatment for Huntington's Disease and Cancer
Unique Targets. Novel Mechanisms. New Medicines. Science in the Service of Medicine VX15 (pepinemab) Antibody Treatment for Huntington’s Disease and Cancer Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Words such as “m
Slide 3: Vaccinex Product Pipeline
Partnered Anti-CD20 Antibody ActivMAb Antibody Platform Research/Preclinical Phase 1 Phase 2 Phase 3 SEMA4D Antibody Platform Vaccinex Product Pipeline CLASSICAL – Lung VX15 (pepinemab) Huntington’s Disease (Orphan Disease and Fast Track Designation) VX15 (pepinemab) Non-Small Cell Lung Cancer BVX20
Slide 4: Introduction to Semaphorin 4D (SEMA4D)
Introduction to Semaphorin 4D (SEMA4D) SEMA4D is an extracellular signaling molecule that regulates the activity of inflammatory cells at sites of injury or cancer SEMA4D signals through PLXNB1 and PLXNB2 receptors to regulate (1) cell cytoskeleton (2) cytokine synthesis and secretion VX15 (pepinema
Slide 5: VX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's Disease
VX15 (pepinemab)/Anti-Semaphorin 4D for Huntington's Disease
Slide 6: Huntington's Disease (HD)
Huntington’s Disease (HD) HD is an autosomal dominant neurodegenerative disease based on a single mutated gene Neuronal degeneration and severe atrophy is observed in multiple brain regions Symptoms usually appear between the ages of 30 to 50 There are currently no approved treatments to alter the c
Slide 7: Glial Cells Undergo Inflammatory Transformation that Aggravates Brain Damage in HD
Glial cells are the most abundant cells in the brain They provide essential functional support to neurons. Glial cells couple glucose transport and metabolism to synaptic activity CNS damage triggers dramatic change in glial cell morphology and function (a) Beneficial in the context of acute focal i
Slide 8: Huntington's Disease Clinical Trial Design
Huntington’s Disease Clinical Trial Design Program granted Orphan Disease and Fast Track Designation by the FDA Division of Neurology Products Database lock and analysis for Cohort A Adapt Cohort B design: sample size and treatment duration based on Cohort A data 2020 36 subjects randomized 1:1 Drug
Slide 9: Clinical Evidence of Improved Brain Metabolic Activity in Frontal Lobe and Adjacent Parietal Regions
Clinical Evidence of Improved Brain Metabolic Activity in Frontal Lobe and Adjacent Parietal Regions VX15 Placebo VX15 (pepinemab) after cross-over * p<0.05 compared to placebo
Slide 10: SIGNAL Cohort A Data Highlights
SIGNAL Cohort A Data Highlights The Cohort A data includes both brain imaging results (FDG-PET and volumetric MRI) as well as quantitative motor and cognitive assessments of treatment effects VX15 (pepinemab) treatment significantly increases metabolic activity as detected by FDG-PET: Previous studi
Slide 11: VX15 (pepinemab) Anti-SEMA4D Antibody for Cancer
VX15 (pepinemab) Anti-SEMA4D Antibody for Cancer
Slide 12: SEMA4D Expression is Concentrated at Invasive Margin of Tumor
SEMA4D Expression is Concentrated at Invasive Margin of Tumor Mammary carcinoma (Tubo.A5) SEMA4D at the invasive margin of the tumor forms a barrier that restricts the infiltration of anti-tumor immune cells Antibodies against SEMA4D neutralize this barrier and “open the gates” of the tumor to the i
Slide 13: SEMA4D Controls Infiltration of Antigen Presenting Dendritic Cells into Tumor
Dendritic cells (DC) express receptor PLXNB1. Binding to SEMA4D restricts penetration of DC into tumor. Antibody blockade of SEMA4D enhances migration and differentiation of DC within tumor Colon26 tumor bearing mice were treated in vivo with control antibody or Anti-SEMA4D Tumors were harvested 27
Slide 14: Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor
Anti-SEMA4D Antibody Increases Cytotoxic T Cells in Tumor T cell exclusion in Colon26 tumor Control group CD8+ T cells (red) do not penetrate the tumor. Most CD8+ cells are within the stroma and vessels Anti-SEMA4D antibody CD8+ T cells infiltrate the interior of the tumor Stroma Tumor Stroma Tumor
Slide 15: Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors: Anti-CTLA-4
Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors Anti-CTLA-4 Combination with anti-SEMA4D Colorectal Cancer Head & Neck Cancer Control αSEMA4D αCTLA-4 αSEMA4D + αCTLA-4 Control αSEMA4D αCTLA-4 αSEMA4D + αCTLA-4 Colon26 MOC1
Slide 16: Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors: Anti-LAG3
Control αSEMA4D αLAG3 αLAG3+αSEMA4D Anti-SEMA4D Antibody Enhances Activity of Immune Checkpoint Inhibitors Anti-LAG3 Combination with anti-SEMA4D Colorectal Cancer
Slide 17: Phase 1b/2 Combination Trial with Avelumab in NSCLC
Phase 1b/2 Combination Trial with Avelumab in NSCLC Trial to evaluate immune infiltration in tumor biopsies and ORR, DoR, PFS Open-label design allows for periodic data updates Co-funded by: Study to enroll up to ~62 subjects with advanced NSCLC Treatment of up to 6 subjects (3 + 3 design) in each o
Slide 18: Combination Melanoma Trial with Nivolumab and with Ipilimumab
Combination Melanoma Trial with Nivolumab and with Ipilimumab Randomized Phase 1 study to enroll up to 60 patients with advanced (stage III or IV) melanoma who have progressed on anti-PD1/L1 based checkpoint inhibitors Trial to evaluate immune infiltration in tumor biopsies, ORR, DoR and PFS VX15/25
Slide 19: Antibody Selection to Multi-Pass Membrane Receptors
Antibody Selection to Multi-Pass Membrane Receptors
Slide 20: ActivMAb Discovery Platform
ActivMAb Discovery Platform Proprietary library-based monoclonal antibody (Mab) discovery technology Allows efficient expression and selection of fully functional IgG antibodies in mammalian cells Employs a fusion protein of full length IgG heavy chain linked to a vaccinia virus membrane protein tha
Slide 21: Research Collaboration with Surface Oncology
Research Collaboration with Announced January 2018 Utilizes Vaccinex’s ActivMAb platform to discover and select monoclonal antibodies to two undisclosed membrane targets Surface Oncology has the option to obtain exclusive worldwide rights to antibodies discovered during the research program Vaccinex
Slide 22: Robust Patent Estate
Robust Patent Estate VX15 (pepinemab) US Patents and Patent Applications Total Patent Franchise US EU Granted / allowed 26 11 Pending 15 13 Key Composition of Matter Claims US No. 8,496,938 issued 7/30/13) Expected Exclusivity to 2030 (before patent term extension) Key Additional Method of Use Claim
Slide 23: Anticipated Milestones
Anticipated Milestones Event Timing Antibody Platform: Expected delivery of selected antibodies to Surface Oncology Q4 2018 Publish SIGNAL Cohort A Data in Huntington’s Disease 2019 ASCO 2019, Anticipated Initial Report of Open Label combination study of VX15 (pepinemab) with avelumab in NSCLC June
Slide 24: Investment Summary
Novel mechanistic approach Lead program, VX15 (pepinemab), is a humanized monoclonal antibody that binds to and blocks a unique target, semaphorin 4D (SEMA4D) Multiple clinical programs in Huntington’s Disease and Oncology Huntington’s Disease – ongoing randomized, placebo-controlled Phase 2 trial E
Slide 25: Vaccinex Corporation
Vaccinex Corporation Clinical-stage immunotherapy company focused on the discovery and development of antibody therapies for neurodegenerative diseases and cancer VCNX (NASDAQ) Recent close $9.99 (8/31) Shares outstanding 11.5M Market cap $115M Headquarters Rochester, NY Employees 43 (34 in R&D) IPO
Slide 26: Executive Management Team
Executive Management Team Maurice Zauderer, Ph.D. Founder, President & Chief Executive Officer Formerly Professor at University of Rochester and at Columbia University. Scott E. Royer, CFA, MBA Chief Financial Officer Formerly CFO, Medical Films Division of Carestream Health. John E. Leonard, Ph.D.
Slide 27: Vaccinex Board of Directors
Vaccinex Board of Directors Albert D. Friedberg Chairman, President and CEO of Friedberg Mercantile Group, a Toronto-based commodities and investment management firm he founded in 1971. He served as Chairman of the Toronto Futures Exchange from March 1985 to June 1988. Alejandro M. Berlin, M.D., MSc
Slide 28: Appendix
Appendix WAccinex
Slide 29: SIGNAL Study: Clinical Evidence of Brain Tissue Preservation
SIGNAL Study: Clinical Evidence of Brain Tissue Preservation Frontal Lobe Parietal Lobe Frontal/Parietal VX15 Placebo VX15 (pepinemab) after cross-over * p<0.05 compared to placebo
Slide 30: Blocking SEMA4D protects against loss of inhibitory Neurons in CVN Murine Model of Alzheimer's Disease
Blocking SEMA4D protects against loss of inhibitory Neurons in CVN Murine Model of Alzheimer’s Disease 30 D. C. Blocking SEMA4D protects against loss of inhibitory neurons in the CVN murine model of AD. Restoration of synaptic activity and, potentially, neural networks could also contribute to signi